Latest Investor Confidence News

US1 Critical Minerals has launched Federal Court proceedings against Apex USA Resources over disputed Rare Earth Elements tenements in California, seeking to secure ownership and prevent disposal amid escalating tensions.

Canyon Resources confirms steady progress on its Minim Martap Bauxite Project in Cameroon, with mining set to start in early 2026 and the first bauxite shipment planned for June. Key infrastructure and equipment deliveries remain on schedule amid ongoing equity funding efforts.

Koba Resources has completed a $4.35 million placement of 87 million shares at 5 cents each, accompanied by 43.5 million free attaching options exercisable at 8 cents until mid-2028, following shareholder approval.

Anax Metals has completed a $2.4 million strategic placement with mining group Gold Valley at a 37.5% premium, while securing a $3.5 million loan to repay convertible notes, positioning the Whim Creek copper project for near-term development.

BSP Financial Group has explained the late filing of a director’s shareholding change, attributing it to delayed confirmation from a financial advisor, while reaffirming its compliance policies.

Locksley Resources has raised A$17 million in an oversubscribed placement led by U.S. institutional investors, accelerating its strategy to develop a domestic supply chain for antimony and rare earths in California.

Antares Metals Ltd has been reinstated to ASX trading following its announcement of a proposed acquisition and capital raising, signaling a pivotal moment for the base metals miner.

Australian Vintage Limited has secured a five-year distribution agreement to represent Invivo's wine portfolio in the UK and Ireland, promising significant revenue and volume growth.

Assetora Limited has raised $500,000 through a private placement, issuing 3.57 million shares with options attached, signaling strong investor confidence in its alternative assets strategy.

Scout Security has made significant strides toward merging with Roo Inc, secured $600,000 in fresh capital, and progressed a new Insurtech partnership, all while managing tight cash flow in the September quarter.

Algorae Pharmaceuticals has independently validated its AI-driven drug combination platform, AlgoraeOS v1, confirming its ability to predict synergistic cancer drug pairs. The company has also launched an upgraded version, AlgoraeOS v2, poised to enhance drug discovery efforts.

Anteris Technologies has secured regulatory green lights for its pivotal PARADIGM trial and raised $25.2 million in capital, advancing its innovative DurAVR® transcatheter heart valve towards commercialisation.